Search Results
Your search for ,NOt matches 22378 pages
Showing 8501 - 8550Tumeur Fibro-Plastique
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Dana-Farber Launches New Center for Prevention and Treatment of BRCA-Related Cancers
Of the tens of thousands of genes in cellular DNA, one group of genes is tasked with ensuring that every cell reproduces itself exactly when it divides to make new cells. Perhaps the best known of these genes are the BRCA genes, which if inherited with a significant alteration, confer a markedly...
After Immigrating From India, Neha Vapiwala, MD, FACR, Followed Her Dream of a Career in Medicine
Neha Vapiwala, MD, FACR, Professor and Vice Chair of Education in the Department of Radiation Oncology and newly appointed Dean of Admissions at the Perelman School of Medicine at the University of Pennsylvania (UPenn), Philadelphia, was born in India to parents who aspired to emigrate to the...
Ashwagandha
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, present updated information on ...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Cambodia
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Cambodia. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Managing Cancer in Older Adults During the COVID-19 Pandemic
The COVID-19 pandemic is an additional competing risk to factor in when making decisions about anticancer treatment for older adults. It poses a potential barrier to equal and evidence-based management of cancer in this group of patients. Implementing geriatric assessments in routine clinical...
David A. Karnofsky’s Early Contributions to Cancer Research Helped Establish Oncology as a Medical Discipline
For nearly 30 years, from the time he was a young resident at the Collis P. Huntington Memorial Hospital for Cancer Research of Harvard University, until his death from lung cancer on August 31, 1969, David A. Karnofsky, MD, dedicated himself to the pursuit of scientific excellence and the...
How to Treat Patients With Multiple Myeloma Cost-Effectively Without Compromising Outcome
The dramatic advances in the diagnosis and treatment of multiple myeloma over the past 20 years have resulted in significant improvements in overall survival, with 5-year relative survival rates now around 50% and more than 60% for patients younger than age 70.1 The proteasome inhibitors...
How the First International Summit on Interventional Pharmacoeconomics Is Sparking Discussion on Reducing Cancer Costs
Three years ago, former Chief Executive Officer of ASCO, Allen S. Lichter, MD, Laurence H. Baker, DO, Professor in the Departments of Internal Medicine and Pharmacology at the University of Michigan Medical School in Ann Arbor; Leonard Saltz, MD, a gastrointestinal oncologist at Memorial Sloan...
Health Groups Oppose Suspending Immigration for Health-Care Providers and Family Members
The Association for Clinical Oncology signed on to a letter from the American Medical Association (AMA) and statements from the Council of Medical Specialty Societies and the American College of Physicians’ Council of Subspecialty Societies expressing concerns about the Trump Administration’s...
BRCA Study: Clinic Is Saving Men’s Lives in Israel
Uriya, age 49, visits Israel’s Rabin Medical Center for a cancer screening. On the surface, he shows no signs of disease. However, results from a study by David Margel, MD, PhD, revealed Uriya is living with prostate cancer at an early yet curable stage. Uriya carries the BRCA gene. Rabin Medical...
For Your Patients: An Expert Q&A on Cancer Disparities and Health Equity
Cancer does not affect all people equally. The phrase “cancer disparities” refers to the differences in the number of new cancer cases as well as differences in cancer outcomes that exist among different populations. Disparities more often negatively affect racial and ethnic minorities, poor...
Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL
The Bruton’s tyrosine kinase (BTK) inhibitors have been one of the most exciting advances in the tre atment of chronic lymphocytic leukemia (CLL) and have led to the development of chemotherapy-free treatments for both treatment-naive as well as relapsed or refractory CLL based on studies where...
Acalabrutinib Improves Progression-Free Survival vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory CLL
As reported in the Journal of Clinical Oncology by Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, Milan, Italy, and colleagues, the phase III ASCEND trial showed significantly prolonged progression-free survival with acalabrutinib monotherapy vs the investigator’s choice of...
Adding Immunotherapy to BRAF/MEK Inhibition in BRAF V600–Mutant Melanoma: First Step on the Journey
As investigators, we were always determined to find the drug to work with BRAF/MEK inhibitor combination therapy. It had come on like a storm and showed us that we could help even those with the most advanced metastatic melanoma, as long as it harbored the magical BRAF V600E mutation.1...
Addition of Atezolizumab to Vemurafenib/Cobimetinib in Unresectable Advanced BRAF V600–Mutant Melanoma
As reported inThe Lancet by Ralf Gutzmer, MD, of Medizinische Hochschule Hannover, Germany, and colleagues, the phase III IMspire150 trial has shown that the addition of atezolizumab to BRAF and MEK inhibitor therapy with vemurafenib and cobimetinib improved progression-free survival in the...
Researchers Outline Need for Evaluation of Gene-Expression Profiling in Melanoma
A consensus statement published in JAMA Dermatology by an international group of melanoma researchers evaluated the use of prognostic gene-expression profile testing to guide clinical management of melanoma.1 The group cautioned against the routine use of currently available gene-expression...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, Drs. Abutalib, Pemmaraju, and Medeiros highlight the clinically aggressive blastic plasmacytoid dendritic cell neoplasm. For each quiz...
Tafasitamab-cxix in the Treatment of Diffuse Large B-Cell Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On July 31, 2020, tafasitamab-cxix, a CD19-directed...
Repurposing Drugs for the Treatment of COVID-19
A vaccine for COVID-19 is currently the Holy Grail, but even if an effective vaccine were developed on a fast-track timetable, it may be effective in only a percentage of people, judging by existing flu vaccines, which show efficacy rates of approximately 45% and vary year by year. Until we have a...
Switch Control Inhibitor for GISTs Harboring Drug-Resistance Mutations: The INVICTUS Trial
In May 2020, the U.S. Food and Drug Administration (FDA) approved ripretinib for patients who have received prior treatment with three or more kinase inhibitors, including imatinib, for advanced gastrointestinal stromal tumors (GIST). The approval was largely based on the findings of the...
Ripretinib Improves Progression-Free Survival vs Placebo in Previously Treated Advanced GIST
As reported inThe Lancet Oncology by Jean-Yves Blay, MD, of Centre Léon Bérard, Lyon, France, and colleagues, the phase III INVICTUS trial has shown that the oral KIT and PDGFRα tyrosine kinase inhibitor ripretinib significantly prolonged progression-free survival vs placebo in patients with...
ASCO Provisional Clinical Update Offers New Recommendations for HBV Management in Patients With Cancer
Oncologists should consider screening all patients with cancer for the hepatitis B virus (HBV) prior to starting systemic anticancer therapy, with a focus on tests that use the hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), total Ig or IgG, and antihepatitis B surface...
Impact of Immune Checkpoint Inhibitors on COVID-19 in Patients With Cancer
In the time of COVID-19, there is much to learn about the intersection of coronavirus and cancer. One area of concern has been whether immunotherapies increase the risk of mortality in patients with cancer who also have COVID-19 infection. “To what extent immune checkpoint inhibition affects...
Reevaluating the Delivery of Palliative Care in the Era of COVID-19
Palliative care services are so crucial to the well-being of patients with cancer that, in 2017, ASCO updated its clinical practice guideline on the integration of palliative care into standard oncology care.1 The updated guideline recommends that all patients with advanced cancer receive dedicated ...
Chemotherapy-Free Approaches in Follicular and Mantle Cell Lymphomas
As chemotherapy and chemoimmunotherapy regimens reach their maximal impact in follicular lymphoma and mantle cell lymphoma, clinicians are turning to chemotherapy-free approaches to achieve better control, less toxicity, and (hopefully) a cure. During the ASCO20 Virtual Education Program, Sonali M. ...
Pet Therapy: How the Cat I Never Wanted Saved My Life
My husband and I adopted our cat, Franklin, on a cold November day. It was one of the last days Andrew felt well enough to leave the house to go anywhere other than to chemotherapy or a doctor’s appointment. Our news at these appointments had shifted toward the negative, with disease progression...
Past CMS and FDA Head Discusses Challenges in U.S. Health-Care Policy and Possible Solutions
As evidenced at this year’s ASCO20 Virtual Scientific Program, oncology science, technology, and clinical practice are evolving at a rapid pace, bringing new challenges to the efficient and ethical practice of cancer care at all levels. To shed light on some of the large-scale public health and...
Rucaparib in Metastatic Castration-Resistant Prostate Cancer With Deleterious BRCA Alterations
As reported in the Journal of Clinical Oncology by Abida and colleagues, the phase II TRITON2 trial has shown that rucaparib produces durable responses in patients with metastatic castration-resistant prostate cancer with deleterious BRCA1 or BRCA2 alterations. The trial supported the May 2020...
Effect of Mammography Screening From Age 40 on Breast Cancer Mortality: Final Results of the UK Age Trial
As reported in The Lancet Oncology by Duffy et al, final results of the UK Age Trial show that initiation of annual mammography screening for breast cancer at age 40 was associated with a significant reduction in breast cancer mortality at 10 years compared with screening beginning at age 50 years, ...
FDA Approves Daratumumab Plus Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
On August 20, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with carfilzomib (Kyprolis) and dexamethasone (DKd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three previous lines of therapy....
ASCO Updates Metastatic Pancreatic Cancer Guideline
ASCO has released an update to its Metastatic Pancreatic Cancer Guideline that includes recommendations for second-line treatment, including early biomarker testing for actionable genomic alterations.1 Last updated in 2018, this new version was triggered by novel evidence related to targeted...
FDA Pipeline: Priority Reviews for Immunotherapy Dose Regimen, Small Cell Lung Cancer; Fast Track Designations in Brain Cancer and Leukemia
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Reviews for a novel dosing regimen for durvalumab as well as for trilaciclib in small cell lung cancer; granted Fast Track designations to treatments for glioblastoma and B-cell acute lymphoblastic leukemia; and issued reports...
Effect of Muscle Mass and Radiodensity on Postoperative Complications and Outcomes of Colon Cancer Surgery
In a retrospective cohort study reported in JAMA Surgery, Xiao et al found that low skeletal muscle index and low skeletal muscle radiodensity were associated with an increased risk of complications and poor outcomes following surgery for colon cancer. Study Details The study involved data on...
Updated Registry Data Confirm Higher COVID-19–Related Mortality in Patients With Cancer
“The distressing intersection of COVID-19 and cancer requires the use of large registries to acknowledge diversity,” stated Solange Peters, MD, PhD, President of the European Society for Medical Oncology (ESMO), in her keynote speech at the American Association for Cancer Research (AACR) Virtual...
Meta-analysis of Overall Survival With Immunotherapy in Patients With Advanced Cancer According to Sex, Age, and Performance Status
In a systematic review and meta-analysis reported in JAMA Network Open, Yang et al found overall survival benefits with immune checkpoint inhibitor treatment vs non–immune checkpoint inhibitor treatment of advanced cancers irrespective of sex, age < 65 years vs ≥ 65 years, or Eastern Cooperative ...
Characteristics of Neuroendocrine Carcinomas of the Gallbladder
In a Korean study reported in the American Journal of Surgical Pathology, Lee et al identified clinicopathologic and immunohistochemical characteristics of neuroendocrine carcinomas of the gallbladder. Study Details The study involved data from 34 patients with gallbladder neuroendocrine carcinomas ...
Tumor Mutational Burden and the Future of Complex Biomarkers
The development of complex biomarkers such as tumor mutational burden (TMB) has enabled clinicians to identify patients more likely to respond to treatment of a variety of cancers, leading to more accurate diagnoses and improved outcomes. Differences in testing assays, however, have produced...
Three Novel Genetic Variants Linked to Male Breast Cancer Discovered
Scientists have newly discovered three genetic changes that increase the risk of breast cancer in men. These findings were published by Maguire et al in the Journal of the National Cancer Institute. The researchers identified three common variations in DNA that predispose men to developing breast...
Association of Surgical Volume Pledge With Short-Term Outcomes After Lung Cancer Resection
In a retrospective study reported in the Journal of Clinical Oncology, Farjah et al found that patients who underwent resection for lung cancer at hospitals and with surgeons meeting Volume Pledge criteria did not have better short-term outcomes compared with patients who received care from...
Molecular Testing in Metastatic Colorectal Cancer: Understanding How, When, and What to Profile
“In line with the emergence of targeted therapies, molecular biomarker testing in metastatic colorectal cancer has evolved over the past decade,” noted Jeanne Tie, MD, MBChB, FRACP, who acknowledged there is confusion about the best ways to use molecular testing in the clinic. Dr. Tie, who is...
Genomic Analysis of Cervical Cancer in Ugandan Patients
Nineteen of the 20 nations with the highest cervical cancer death rates are in sub-Saharan Africa. Now an international team has published the first comprehensive genomic study of cervical cancers in sub-Saharan Africa, with a focus on tumors from 212 Ugandan patients with cervical cancer. Their...
ASCO Members Can Access Special Offer for PPE Through Project N95: Register by August 24
Project N95, a not-for-profit organization, is offering access to ASCO’s qualifying U.S. members who are having difficulty obtaining personal protective equipment (PPE) for their patients and staff. Qualifying ASCO members will be able to make a one-time bulk purchase of the following PPE...
Brigatinib vs Crizotinib in ALK Inhibitor–Naive Patients With ALK-Positive Advanced NSCLC
As reported in the Journal of Clinical Oncology by D. Ross Camidge, MD, PhD, and colleagues, a second prespecified interim analysis of the pivotal phase III ALTA-1L trial has shown maintained progression-free survival benefit with brigatinib vs crizotinib in ALK inhibitor–naive patients with...
Risk-Stratified Stem Cell Transplant and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma
As reported in the Journal of Clinical Oncology by Knörr et al, a trial of risk-stratified treatment for relapsed pediatric anaplastic large cell lymphoma (ALCL) showed that allogeneic stem cell transplantation (SCT) was effective in patients with high-risk relapse, whereas autologous SCT was not...
Activity of Olaparib and Durvalumab in Germline BRCA-Mutated Metastatic Breast Cancer
As reported in The Lancet Oncology by Susan M. Domchek, MD, and colleagues, the combination of olaparib and durvalumab showed activity in a cohort of patients with germline BRCA-mutated, HER2-negative metastatic breast cancer enrolled in a phase I/II basket study (MEDIOLA). Study Details In the...
Balancing Efficacy and Safety of Targeted Therapy in Breast Cancer Care
Novel targeted therapies have increased the likelihood of cure and prolonged survival in many patients with advanced breast cancer (Table 1), but these new agents also carry toxicity profiles that vary greatly from those of traditional chemotherapy. During the ASCO20 Virtual Education Program,...
Aspirin May Accelerate the Progression of Advanced Cancers in Older Adults
Results from a recent clinical trial indicated that for older adults with advanced cancer, initiating aspirin treatment may increase their risk of disease progression and mortality. These findings were published by McNeil et al in the Journal of the National Cancer Institute. Study Background and...
Early Rituximab Intensification in R-CHOP for Diffuse Large B-Cell Lymphoma
As reported in the Journal of Clinical Oncology by Pieternella Johanna Lugtenburg, MD, PhD, and colleagues, the phase III Haemato-Oncology Foundation for Adults in the Netherlands (HOVEN)/ Nordic Lymphoma Group HOVON-84 trial showed that early rituximab intensification in R-CHOP-14 (rituximab plus...
Study Finds Radiotherapy May Be Associated With Long-Term Impact on the Cardiovascular and Metabolic Health of Childhood Cancer Survivors
A study by Wilson et al investigating the impact of radiation therapy on adult survivors of pediatric abdominal and pelvic tumors has found that these survivors were significantly more likely to have insulin resistance, high levels of triglycerides, and low levels of high-density lipoproteins...
